Moventig (Naloxegol)

Naloxegol selectively blocks peripheral μ‑opioid receptors in the gastrointestinal tract. By preventing opioids from inhibiting intestinal peristalsis, it restores normal motility and facilitates stool formation while leaving central opioid receptors untouched, so pain relief is maintained.

The dose of Moventig is determined by the prescribing healthcare professional based on the patient’s clinical condition, opioid regimen, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for naloxegol during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Moventig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to naloxegol is methylnaltrexone, another peripheral opioid antagonist. Both agents aim to relieve opioid‑induced constipation, but naloxegol is an oral tablet while methylnaltrexone is administered subcutaneously. Choice between them often depends on patient preference, route of administration, and specific safety considerations.

Moventig tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Moventig is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed, chewed, or split, to ensure proper absorption and maintain its intended release characteristics.

Serious adverse events associated with naloxegol include intestinal obstruction, severe abdominal pain, allergic reactions such as rash or angioedema, pancreatitis, and significant dehydration. Patients should seek immediate medical attention if they experience any of these symptoms.

Moventig is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction, severe hepatic impairment, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a history of hypersensitivity to naloxegol or any of the tablet’s excipients.